Central administration of GLP-1RAs reduces food intake, likely via GLP-1 receptorexpressing regions in the hypothalamus and brainstem (Kastin and Akerstrom, 2003), many of which are also estrogen targets (Kanoski et al., 2011), supporting a potential interaction between these systems (Miller, 2012)
The solution is not to force down large portions
But the problem Im really seeing is that theres often no time in healthcare systems or in these asynchronous platforms where people are getting comprehensive care
Both Wegovy and Ozempic contain the GLP-1 agonist semaglutide, but Wegovy is prescribed for long-term weight management and certain forms of liver disease, while Ozempic is used to control blood sugar in type 2 diabetes and help protect the heart and kidneys
According to the ADA 2018 Guidelines [1], treatment for T2DM should start with monotherapy unless A1c is greater or equal than 9.0%, when dual therapy must be considered